| 2016-10-11 07:10:38|
CRIS 07:10 10/11 10/11/16
Curis expands pipeline with CA-327
Curis announced the expansion of its pipeline with CA-327, an oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1, or PD-L1, and T-cell immunoglobulin and mucin domain containing protein-3, or TIM-3. Curis licensed the PD-1/ TIM-3 antagonist program, and designated CA-327 as the development candidate, by exercising its option under the collaboration, license and option agreement established with Aurigene in January 2015. The in-license of CA-327 comes three months after the collaboration's first oral immuno-oncology program entered the clinic and less than a month after a $24.5M investment in Curis by Aurigene.